Dynamic Technology Lab Private Ltd Decreases Stake in OraSure Technologies, Inc. (NASDAQ:OSUR)

Dynamic Technology Lab Private Ltd decreased its holdings in shares of OraSure Technologies, Inc. (NASDAQ:OSUR) by 54.3% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 53,233 shares of the medical instruments supplier’s stock after selling 63,144 shares during the quarter. Dynamic Technology Lab Private Ltd’s holdings in OraSure Technologies were worth $228,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of the business. Millennium Management LLC raised its position in shares of OraSure Technologies by 727.5% during the 2nd quarter. Millennium Management LLC now owns 2,021,126 shares of the medical instruments supplier’s stock valued at $8,610,000 after buying an additional 1,776,867 shares during the period. Acadian Asset Management LLC lifted its position in OraSure Technologies by 38.1% in the second quarter. Acadian Asset Management LLC now owns 2,195,582 shares of the medical instruments supplier’s stock valued at $9,349,000 after buying an additional 605,324 shares during the last quarter. American Century Companies Inc. increased its position in shares of OraSure Technologies by 30.1% during the second quarter. American Century Companies Inc. now owns 1,809,897 shares of the medical instruments supplier’s stock valued at $7,710,000 after acquiring an additional 418,603 shares during the last quarter. Renaissance Technologies LLC raised its stake in shares of OraSure Technologies by 20.6% in the 2nd quarter. Renaissance Technologies LLC now owns 2,288,443 shares of the medical instruments supplier’s stock valued at $9,749,000 after acquiring an additional 391,100 shares during the period. Finally, Massachusetts Financial Services Co. MA acquired a new position in shares of OraSure Technologies in the 2nd quarter worth approximately $1,602,000. 93.50% of the stock is currently owned by institutional investors and hedge funds.

OraSure Technologies Stock Up 2.6 %

OSUR stock opened at $3.90 on Tuesday. The business has a 50 day moving average price of $4.08 and a 200 day moving average price of $4.28. OraSure Technologies, Inc. has a fifty-two week low of $3.72 and a fifty-two week high of $8.45. The stock has a market cap of $290.92 million, a price-to-earnings ratio of 26.00 and a beta of 0.05.

OraSure Technologies (NASDAQ:OSUR) last released its quarterly earnings results on Wednesday, November 6th. The medical instruments supplier reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.08) by $0.02. OraSure Technologies had a return on equity of 3.55% and a net margin of 5.07%. The company had revenue of $39.92 million for the quarter, compared to analyst estimates of $38.97 million. During the same quarter in the previous year, the company posted $0.27 earnings per share. The firm’s revenue was down 55.2% compared to the same quarter last year. As a group, sell-side analysts anticipate that OraSure Technologies, Inc. will post -0.09 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms have recently commented on OSUR. StockNews.com upgraded OraSure Technologies from a “hold” rating to a “buy” rating in a research report on Friday, October 4th. Evercore ISI lifted their target price on OraSure Technologies from $4.50 to $5.00 and gave the company an “in-line” rating in a report on Wednesday, August 7th.

About OraSure Technologies

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company’s products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.